Mizagliflozin is under clinical development by Vogenx and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs for Hypoglycemia have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mizagliflozin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mizagliflozin overview

Mizagliflozin is under development for the treatment of postbariatric hypoglycemia (PBH). It is administered through oral route in the form of liquid or encapsulated formulation. The drug candidate acts by targeting selective inhibitor of sodium dependent glucose cotransporter 1 (SGLT1).

Vogenx overview

Vogenx is focused on developing novel therapeutics to address unmet medical need of patients suffering from rare disease. Vogenx is headquartered in Durham, North Carolina, the US.

For a complete picture of Mizagliflozin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.